Related Experiment Video
Updated: Jun 22, 2025
06:28
Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
Published on: June 4, 2020
6.8K
Advancing Thrombosis Research: A Novel Device for Measuring Clot Permeability
Elia Landi1, Marco Mugnaini1, Tunahan Vatansever1
1Department of Information Engineering and Mathematics, University of Siena, 53100 Siena, Italy.
Sensors (Basel, Switzerland)
|June 27, 2024
Summary
A new portable device accurately measures blood clot permeability, a key indicator for assessing thrombotic risk. This innovation aids in better patient stratification and management of thromboembolic diseases.
Area of Science:
- Biomedical Engineering
- Hematology
- Medical Devices
Background:
- Thromboembolism is a leading cause of mortality globally, necessitating accurate risk assessment for effective prophylaxis and treatment.
- Current methods for stratifying thrombotic risk are insufficient, highlighting the need for improved understanding of clot properties like fibrin clot permeability.
- Existing methods for measuring clot permeability lack standardization, precision, and portability, hindering their clinical application.
Purpose of the Study:
- To develop and validate a novel, portable, and cost-effective system for measuring blood clot permeability.
- To enhance the precision and sensitivity of clot characteristic analysis for improved thrombotic risk assessment.
- To provide a tool that can differentiate clot permeability between healthy individuals and those at high cardiovascular risk.
Main Methods:
- Development of a pressure-based system adhering to Darcy's law for measuring in vitro clot permeability.
- Automated measurement of plasma or fibrinogen clots within specialized holders.
- Characterization of the device using plasma and fibrinogen clots from Behcet patients and matched healthy controls.
Main Results:
- The novel device demonstrated high precision and sensitivity in distinguishing clot permeability.
- Significant differences in plasma clot permeability were observed between Behcet patients and controls (p < 0.001).
- Similar significant differences were confirmed in fibrin clots derived from patients versus controls (p < 0.001).
Conclusions:
- The developed device is feasible, effective, portable, and cost-efficient for measuring clot permeability.
- This innovation offers a valuable tool for healthcare providers to better stratify thrombotic risk.
- Improved thrombotic risk stratification can lead to tailored interventions, enhanced patient outcomes, and reduced healthcare costs in managing thromboembolic diseases.
